SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sobi’s pozdeutinurad lowers serum urate in Phase 3 study

Sobi said its drug candidate pozdeutinurad durably lowered serum urate levels in a Phase 3 study.

SquawkNews Desk 1 updates Updated Oct 29, 2026, 07:16 AM UTC

Story updates

07:16:09 AM UTC
SquawkNews
Sobi: Pozdeutinurad senkt Serumuratwerte in Phase-3-Studie über zwölf Monate Sobi hat mit Pozdeu

Related stories

ResMed Publishes Q1 FY2027 Earnings Call Transcript ResMed published a transcript of its Q1 fiscal 2027 earnings call. M impact | EQUITY | Oct 30, 2026, 06:15 AM UTC Microsoft Prices $25 Billion Senior Unsecured Notes Offering Microsoft announced pricing for $25 billion in aggregate principal amount of senior unsecured notes. H impact | EQUITY | Oct 30, 2026, 06:12 AM UTC Asian session market picture: S&P 500 -0.93%, Nasdaq 100 -2%; USD/JPY -0.01%, WTI +1.32%, 1810 leads volume Asian session market picture. US index futures: S and P futures is down 0.93 percent, Nasdaq futures is down 2 percent, Dow futures is down 0.15 percent and Russell futures is down M impact | EQUITY | Oct 30, 2026, 06:00 AM UTC Strategy Eyes More Bitcoin Buys, Cites $30 Billion Credit Capacity Strategy is looking to finance additional Bitcoin purchases through preferred-share offerings. Executive Chairman Michael Saylor said the company has capacity to create up to $30 b M impact | EQUITY | Oct 30, 2026, 05:56 AM UTC Technip Energies Flags Hormuz Logistics Risk to Middle East Projects in 2027 M impact | EQUITY | Oct 30, 2026, 05:55 AM UTC Accenture and Unilever Partner to Scale Digital Twins Across Factories Accenture and Unilever are partnering to scale AI-enabled digital twins across global factories. M impact | EQUITY | Oct 30, 2026, 05:54 AM UTC